Phaseline

Companies › XyloCor Therapeutics

XyloCor Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XC001
Gene therapy delivered via percutaneous catheter
–Phase 2Refractory AnginaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07048808XC001Phase 2Refractory AnginaCardiovascularJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nyrada AllRock Bio Zomagen Biosciences Agiana Pharmaceuticals Cardurion Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.